NCT02577406 2025-05-18
IDHENTIFY
Celgene
Phase 3 Completed
Clinical Trials
10 trialsNCT02627677 2021-11-26
OPTIC-2L
Takeda
Phase 3 Terminated
NCT02130557 2021-05-18
A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Pfizer
Phase 3 Completed
NCT00568633 2019-09-24
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
Phase 3 Terminated
NCT01511289 2016-02-24
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
Il-Yang Pharm. Co., Ltd.
Phase 3 Completed
NCT01650805 2014-11-17
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Ariad Pharmaceuticals
Phase 3 Terminated
NCT00519090 2011-11-07
ENEST
Novartis
Phase 3 Terminated
NCT00422890 2011-07-11
Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
Technische Universität Dresden
Phase 3 Completed
NCT00521664 2011-05-19
A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups
Technische Universität Dresden
Phase 3 Completed
NCT00306332 2009-08-18
T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation
Radboud University Medical Center
Phase 3 Terminated